Abstract

In September 2006, panitumumab (Vectibix; Amgen), a fully human antibody against the epidermal growth factor receptor (EGFR), was approved by the FDA for the treatment of patients with EGFR-expressing metastatic colorectal cancer with disease progression on or following fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy regimens.

Author affiliations

1. Leonard Saltz is at the Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
   Email: saltzl@MSKCC.ORG
2. Chris Easley is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK.
   ceasley@uk.imshealth.com
3. Peter Kirkpatrick is at Nature Reviews Drug Discovery.
   Email: p.kirkpatrick@nature.com

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.